Nicola Wealth Management LTD. Has $5.69 Million Holdings in Perrigo Company plc $PRGO

Key Points

• Nicola Wealth Management LTD. increased its holdings in Perrigo Company plc by 27.7% in Q1, owning 203,000 shares valued at approximately $5.69 million.
• Several hedge funds, including Geneos Wealth Management and First Horizon Advisors, significantly boosted their positions in Perrigo during the same quarter.
• Perrigo's stock recently opened at $22.52, with a 1-year low of $21.03 and a 1-year high of $30.93, while the company has announced a quarterly dividend of $0.29.

Nicola Wealth Management LTD. grew its stake in Perrigo Company plc (NYSE:PRGO - Free Report) by 27.7% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 203,000 shares of the company's stock after purchasing an additional 44,000 shares during the quarter. Nicola Wealth Management LTD. owned about 0.15% of Perrigo worth $5,692,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in PRGO. American Assets Inc. acquired a new position in shares of Perrigo in the 4th quarter valued at $386,000. Baird Financial Group Inc. lifted its stake in shares of Perrigo by 8.8% in the 4th quarter. Baird Financial Group Inc. now owns 13,029 shares of the company's stock valued at $335,000 after purchasing an additional 1,053 shares during the period. Nomura Holdings Inc. acquired a new position in shares of Perrigo in the 4th quarter valued at $465,000. Quantinno Capital Management LP lifted its stake in shares of Perrigo by 687.2% in the 4th quarter. Quantinno Capital Management LP now owns 155,033 shares of the company's stock valued at $3,986,000 after purchasing an additional 135,338 shares during the period. Finally, ProShare Advisors LLC lifted its stake in shares of Perrigo by 16.5% in the 4th quarter. ProShare Advisors LLC now owns 1,331,919 shares of the company's stock valued at $34,244,000 after purchasing an additional 188,282 shares during the period. Institutional investors and hedge funds own 95.91% of the company's stock.

Insider Buying and Selling

In other news, EVP Robert Willis bought 1,488 shares of the business's stock in a transaction that occurred on Friday, August 22nd. The stock was acquired at an average cost of $24.10 per share, for a total transaction of $35,860.80. Following the purchase, the executive vice president owned 41,939 shares of the company's stock, valued at approximately $1,010,729.90. This trade represents a 3.68% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Eduardo Guarita Bezerra bought 3,000 shares of the business's stock in a transaction that occurred on Monday, August 18th. The stock was purchased at an average price of $22.74 per share, with a total value of $68,220.00. Following the completion of the purchase, the chief financial officer directly owned 48,949 shares in the company, valued at $1,113,100.26. The trade was a 6.53% increase in their position. The disclosure for this purchase can be found here. Insiders have purchased 10,118 shares of company stock worth $232,699 over the last 90 days. 0.70% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

PRGO has been the subject of a number of recent analyst reports. Canaccord Genuity Group lowered their price objective on shares of Perrigo from $42.00 to $40.00 and set a "buy" rating for the company in a research report on Thursday, August 7th. JPMorgan Chase & Co. lowered their price objective on shares of Perrigo from $38.00 to $35.00 and set an "overweight" rating for the company in a research report on Thursday, August 7th. Finally, Wall Street Zen upgraded Perrigo from a "hold" rating to a "buy" rating in a report on Friday, September 5th. Two equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $33.00.

Perrigo Stock Down 1.8%

Shares of NYSE PRGO traded down $0.39 during mid-day trading on Tuesday, hitting $21.36. The company had a trading volume of 1,523,986 shares, compared to its average volume of 1,485,331. The company has a market capitalization of $2.94 billion, a PE ratio of -36.83 and a beta of 0.48. The firm has a 50-day simple moving average of $24.91 and a two-hundred day simple moving average of $26.02. The company has a current ratio of 2.32, a quick ratio of 1.24 and a debt-to-equity ratio of 0.81. Perrigo Company plc has a one year low of $21.03 and a one year high of $30.93.

Perrigo (NYSE:PRGO - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported $0.57 earnings per share for the quarter, missing the consensus estimate of $0.59 by ($0.02). The company had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.08 billion. Perrigo had a negative net margin of 1.86% and a positive return on equity of 9.09%. Perrigo's revenue was down .9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.53 EPS. On average, equities analysts expect that Perrigo Company plc will post 2.56 EPS for the current year.

Perrigo Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 16th. Stockholders of record on Friday, August 29th will be issued a $0.29 dividend. The ex-dividend date is Friday, August 29th. This represents a $1.16 annualized dividend and a dividend yield of 5.4%. Perrigo's dividend payout ratio (DPR) is presently -200.00%.

Perrigo Company Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.